<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04474704</url>
  </required_header>
  <id_info>
    <org_study_id>2020H0264</org_study_id>
    <nct_id>NCT04474704</nct_id>
  </id_info>
  <brief_title>Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia</brief_title>
  <official_title>Use of Cheetah® Non-invasive Cardiac Monitoring System to Guide Discontinuation of Postpartum Magnesium Sulfate in Women With Severe Preeclampsia: A Pilot Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single site pilot randomized, controlled, trial randomizing patients with PE with
      severe features to one of 2 groups:

        -  24 hours of postpartum magnesium sulfate (current arbitrary standard of care)

        -  Using the Cheetah® device to aid in an individualized duration of magnesium sulfate.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating duration of magnesium sulfate use in the postpartum period defined as the duration in hours between delivery and discontinuation of magnesium sulfate.</measure>
    <time_frame>up to 36 hours postpartum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluating number of hospital readmission</measure>
    <time_frame>up to 4 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating change in arterial blood pressure (systolic and diastolic)</measure>
    <time_frame>up to 36 hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating change in cardiac output</measure>
    <time_frame>up to 36 hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating change in heart rate</measure>
    <time_frame>up to 36 hours postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating incidence of need to restart magnesium sulfate</measure>
    <time_frame>up to 1 week postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Preeclampsia With Severe Features</condition>
  <arm_group>
    <arm_group_label>Cheetah® non-invasive cardiac monitoring system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 36 hours postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>24 hours of postpartum magnesium sulfate (current arbitrary standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cheetah® non-invasive cardiac monitoring system</intervention_name>
    <description>Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))</description>
    <arm_group_label>Cheetah® non-invasive cardiac monitoring system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>24 hours of postpartum magnesium sulfate</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preeclampsia with severe features, diagnosed using the American Congress of
             Obstetricians and Gynecologists (ACOG) standard criteria 4 requiring magnesium sulfate

          -  Females older than 18 years of age

          -  Singleton pregnancy

          -  Gestational age greater than 24 0/7 weeks

          -  The patient is physically and mentally able to understand the informed consent and is
             willing to participate in this study

          -  Able to speak English or Spanish

        Exclusion Criteria:

          -  Multiple gestation

          -  Prisoners

          -  Patients with chronic renal insufficiency or epilepsy

          -  Known cardiovascular disease

          -  Patients with contraindications to magnesium sulfate use (e.g. myasthenia gravis)

          -  Patients with eclampsia or HELLP syndrome

          -  Contraindications for magnesium sulfate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maged Costantine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maged Costantine, MD</last_name>
    <phone>614-293-2222</phone>
    <email>Maged.Costantine@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Bartholomew, RN</last_name>
    <phone>614-685-3229</phone>
    <email>anna.bartholomew@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Maged Costantine, MD</last_name>
      <phone>614-293-2222</phone>
      <email>Maged.Costantine@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Bartholomew, RN</last_name>
      <phone>614-685-3229</phone>
      <email>anna.bartholomew@osumc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Maged Costantine</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <keyword>preeclampsia with severe features</keyword>
  <keyword>magnesium sulfate</keyword>
  <keyword>Systemic Vascular Resistance</keyword>
  <keyword>non-invasive cardiac monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

